L. Christian Rump

TL;DR: In this article, the authors investigated whether an alternative technology using endovascular ultrasound renal denervation reduces ambulatory blood pressure in patients with hypertension in the absence of antihypertensive medications.

TL;DR: Single-dose fresolimumab was well tolerated in patients with primary resistant FSGS, with pustular rash the only adverse event in two patients and the mean dose-normalized Cmax and area under the curve were independent of dose.

TL;DR: The rationale, design and first baseline data from the Global SYMPLICITY registry are presented, and a benefit from renal denervation in a variety of conditions such as chronic kidney disease, glucose intolerance, sleep apnoea and heart failure are suggested.

TL;DR: It is suggested that nephrin Y1193 serves as a molecular switch that determines the integrity of the slit diaphragm by functional competition between β-arrestin2 and podocin and opens therapeutic avenues for glomerular diseases.

TL;DR: The importance of a renal biopsy in the work-up of ARF even in patients with known malignant diseases is shown, as well as the need for adequate dose-adjusted chemotherapy (CHOP) in the follow-up.